Skip to main content

Advertisement

SpringerLink
Log in

First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802. https://doi.org/10.2967/jnumed.117.203539.

    Article  CAS  PubMed  Google Scholar 

  2. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1847–56. https://doi.org/10.1007/s00259-008-0778-1.

    Article  CAS  PubMed  Google Scholar 

  3. Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. (225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38. https://doi.org/10.1007/s00259-018-4167-0.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany

    Hendrik Rathke, Clemens Kratochwil, Frederik L. Giesel & Uwe Haberkorn

  2. European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany

    Frank Bruchertseifer, Christos Apostolidis & Alfred Morgenstern

  3. Urology Center Mannheim, Mannheim, Germany

    Hanno Keller

  4. Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany

    Frederik L. Giesel & Uwe Haberkorn

Authors
  1. Hendrik Rathke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Bruchertseifer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clemens Kratochwil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hanno Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederik L. Giesel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christos Apostolidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Uwe Haberkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alfred Morgenstern
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hendrik Rathke.

Ethics declarations

Conflict of interest

CK and UH are patent holder of PSMA-617. AM, FB, FLG, CA, CK, and UH are holders of patent application on treatment of PSMA expressing cancers with 225Ac. The other authors declare no conflict of interests.

Ethical approval

All procedures performed in this retrospective evaluation involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards

Informed consent

Informed consent and consent for publication were obtained from the individual participant included in the study. This is a case report from clinical practice; no trial registration is needed for this kind of publication.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Oncology - Genitourinary

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rathke, H., Bruchertseifer, F., Kratochwil, C. et al. First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT. Eur J Nucl Med Mol Imaging 48, 311–312 (2021). https://doi.org/10.1007/s00259-020-04875-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-020-04875-y

Search

Navigation